Home | About us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionContact Us   |  Subscribe   |  Advertise   |  Login  Page layout
Wide layoutNarrow layoutFull screen layout
Lung India Official publication of Indian Chest Society  
  Users Online: 996   Home Print this page  Email this page Small font size Default font size Increase font size
Year : 2014  |  Volume : 31  |  Issue : 3  |  Page : 249-259

Usage patterns of biomarkers in non-small-cell lung cancer patients in India: Findings from a systematic review and survey

1 Department of Hemato-Oncology Clinic, Vedanta Institute of Medical Sciences, Ahmedabad, Gujarat, India
2 Department of Pathology, Rajiv Gandhi Cancer Institute, New Delhi, India
3 Clinical Development (India), SFJ Pharmaceuticals Group, Strategic Funding and Joint-Development, The Gemini, Singapore

Correspondence Address:
Dr. Divya Mishra
Associate Director, Clinical Development (India), SFJ Pharmaceuticals Group, Strategic Funding and Joint-Development, The Gemini
Login to access the Email id

Source of Support: This study was supported by Pfizer India Private Limited, Mumbai, India, The corresponding author was employed with Pfizer at the time of conduct and analysis of this study., Conflict of Interest: None

DOI: 10.4103/0970-2113.135767

Rights and Permissions

Introduction: Personalized medicine has facilitated improved management of non-small cell lung cancer (NSCLC) patients by identifying predictive and prognostic biomarkers for enhanced efficiency of detection and efficacy of treatment. This systematic review and survey assessed the patterns of biomarker usage, molecular testing techniques to diagnose patients with NSCLC in India and testing techniques recommended by cancer societies. Materials and Methods: Studies were retrieved from Embase, PubMed, and Cochrane databases for the last 12 years, using relevant search strategies as per the Cochrane methodology for systematic reviews. Outcomes of interest were biomarkers for NSCLC, patterns of biomarker testing, diagnostic methods, guidelines and cost of biomarker testing. Results: In all, 499 studies were identified for screening and 17 primary publications were included in the review. Epidermal growth factor receptor (EGFR) expression and epithelial markers (particularly cytokeratins (CK)) were the most commonly reported biomarkers (7/17) and immunohistochemical (IHC) staining was the most common technique for detection of biomarkers. The frequency of EGFR mutations was higher among women than men. Significantly elevated levels of CK-18 were observed in patients with squamous cell carcinoma and of CK-19 in patients with adenocarcinoma, squamous cell carcinoma, and NSCLC (P < 0.001). Prognostic or predictive role of cytokines and angiogenic markers as well as DNA expression were evaluated. The survey also showed that IHC was the most common technique for detection of biomarkers. Conclusions: This systematic review and survey provides valuable information on biomarker usage in the Indian population, and highlights the need for initiatives required for future biomarker testing in India.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded583    
    Comments [Add]    

Recommend this journal